+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Respiratory Diseases Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030

  • ID: 5292719
  • Report
  • February 2021
  • Region: Global
  • The Business Research Company
Respiratory Diseases Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus. It provides strategists, marketers and senior management with the critical information they need to assess the increasing demand for respiratory diseases drugs which play a critical role in the treatment of patients with COVID-19.







Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:

Where is the largest and fastest growing market for the respiratory diseases drugs market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Respiratory Diseases Drugs Market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider respiratory diseases drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The respiratory diseases drugs market section of the report gives context. It compares the respiratory diseases drugs market with other segments of the respiratory diseases drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, respiratory diseases drugs indicators comparison.

Scope

Markets Covered:
1) By Type: Anti-Asthmatics and COPD Drugs; Cough and Cold Preparations
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Companies Mentioned: GlaxosmithKline Plc; AstraZeneca Plc; Merck & Co; Novartis AG; Johnson & Johnson

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, respiratory diseases drugs indicators comparison.

Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Frequently Asked Questions about the Global Respiratory Diseases Drugs Market

What is the estimated value of the Global Respiratory Diseases Drugs Market?

The Global Respiratory Diseases Drugs Market was estimated to be valued at $79.8 billion in 2021.

What is the growth rate of the Global Respiratory Diseases Drugs Market?

The growth rate of the Global Respiratory Diseases Drugs Market is 5.5%, with an estimated value of $98.8 billion by 2025.

What is the forecasted size of the Global Respiratory Diseases Drugs Market?

The Global Respiratory Diseases Drugs Market is estimated to be worth $98.8 billion by 2025.

Who are the key companies in the Global Respiratory Diseases Drugs Market?

Key companies in the Global Respiratory Diseases Drugs Market include GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co and Johnson & Johnson.

Table of Contents

1. Executive Summary2. Report Structure
3. Respiratory Diseases Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations
4. Respiratory Diseases Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products
5. Respiratory Diseases Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers
6. Respiratory Diseases Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth
7. Respiratory Diseases Drugs Market Trends and Strategies8. Impact of COVID-19 on Respiratory Diseases Drugs
9. Respiratory Diseases Drugs Market Size and Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.2.1. Drivers of the Market
9.2.2. Restraints on the Market
9.3. Forecast Market Growth, Value ($ Billion)
9.3.1. Drivers of the Market
9.3.2. Restraints on the Market
10. Respiratory Diseases Drugs Market Regional Analysis
10.1. Global Respiratory Diseases Drugs Market, 2020, by Region, Value ($ Billion)
10.2. Global Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
10.3. Global Respiratory Diseases Drugs Market, Growth and Market Share Comparison, by Region
11. Respiratory Diseases Drugs Market Segmentation
11.1. Global Respiratory Diseases Drugs Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Anti-Asthmatics and COPD Drugs
  • Cough and Cold Preparations
11.2. Global Respiratory Diseases Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies/ Drug Stores
  • Others
11.3. Global Respiratory Diseases Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Oral
  • Parenteral
  • Others
11.4. Global Respiratory Diseases Drugs Market, Segmentation by Drug Classification, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Branded Drugs
  • Generic Drugs
11.5. Global Respiratory Diseases Drugs Market, Segmentation by Mode of Purchase, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Prescription-Based Drugs
  • Over-The-Counter Drugs

12. Respiratory Diseases Drugs Market Metrics
12.1. Respiratory Diseases Drugs Market Size, Percentage of GDP, 2015-2025, Global
12.2. Per Capita Average Respiratory Diseases Drugs Market Expenditure, 2015-2025, Global
13. Asia-Pacific Respiratory Diseases Drugs Market
13.1. Asia-Pacific Respiratory Diseases Drugs Market Overview
  • Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
13.2. Asia-Pacific, Respiratory Diseases Drugs Market, 2020, by Country, Value ($ Billion)
13.3. Asia-Pacific, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
13.4. Asia-Pacific, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
13.5. Asia-Pacific, Respiratory Diseases Drugs Market Metrics
13.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2025, Asia-Pacific Countries
13.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2020, Asia-Pacific Countries
13.6. Asia-Pacific Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7. Asia-Pacific Respiratory Diseases Drugs Market: Country Analysis
13.7.1. China Respiratory Diseases Drugs Market
13.7.1.1. China Respiratory Diseases Drugs Market Overview
13.7.1.2. China Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.1.3. China Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2. Australia Respiratory Diseases Drugs Market
13.7.2.1. Australia Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2.2. Australia Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.3. Hong Kong Respiratory Diseases Drugs Market
13.7.3.1. Hong Kong Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4. India Respiratory Diseases Drugs Market
13.7.4.1. India Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4.2. India Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5. Indonesia Respiratory Diseases Drugs Market
13.7.5.1. Indonesia Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5.2. Indonesia Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6. Japan Respiratory Diseases Drugs Market
13.7.6.1. Japan Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6.2. Japan Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.7. Malaysia Respiratory Diseases Drugs Market
13.7.7.1. Malaysia Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.8. New Zealand Respiratory Diseases Drugs Market
13.7.8.1. New Zealand Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.9. Philippines Respiratory Diseases Drugs Market
13.7.9.1. Philippines Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.10. Singapore Respiratory Diseases Drugs Market
13.7.10.1. Singapore Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11. South Korea Respiratory Diseases Drugs Market
13.7.11.1. South Korea Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11.2. South Korea Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.12. Thailand Respiratory Diseases Drugs Market
13.7.12.1. Thailand Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.13. Vietnam Respiratory Diseases Drugs Market
13.7.13.1. Vietnam Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14. Western Europe Respiratory Diseases Drugs Market
14.1. Western Europe Respiratory Diseases Drugs Market Overview
14.2. Western Europe, Respiratory Diseases Drugs Market, 2020, by Country, Value ($ Billion)
14.3. Western Europe, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
14.4. Western Europe, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
14.5. Western Europe, Respiratory Diseases Drugs Market Metrics
14.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2025, Western Europe Countries
14.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2020, Western Europe Countries
14.6. Western Europe Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7. Western Europe Respiratory Diseases Drugs Market: Country Analysis
14.7.1. Austria Respiratory Diseases Drugs Market
14.7.1.1. Austria Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.2. Belgium Respiratory Diseases Drugs Market
14.7.2.1. Belgium Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.3. Denmark Respiratory Diseases Drugs Market
14.7.3.1. Denmark Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.4. Finland Respiratory Diseases Drugs Market
14.7.4.1. Finland Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5. France Respiratory Diseases Drugs Market
14.7.5.1. France Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5.2. France Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6. Germany Respiratory Diseases Drugs Market
14.7.6.1. Germany Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6.2. Germany Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.7. Ireland Respiratory Diseases Drugs Market
14.7.7.1. Ireland Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.8. Italy Respiratory Diseases Drugs Market
14.7.8.1. Italy Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.9. Netherlands Respiratory Diseases Drugs Market
14.7.9.1. Netherlands Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.10. Norway Respiratory Diseases Drugs Market
14.7.10.1. Norway Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.11. Portugal Respiratory Diseases Drugs Market
14.7.11.1. Portugal Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.12. Spain Respiratory Diseases Drugs Market
14.7.12.1. Spain Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.13. Sweden Respiratory Diseases Drugs Market
14.7.13.1. Sweden Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.14. Switzerland Respiratory Diseases Drugs Market
14.7.14.1. Switzerland Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15. UK Respiratory Diseases Drugs Market
14.7.15.1. UK Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15.2. UK Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15. Eastern Europe Respiratory Diseases Drugs Market
15.1. Eastern Europe Respiratory Diseases Drugs Market Overview
15.2. Eastern Europe, Respiratory Diseases Drugs Market, 2020, by Country, Value ($ Billion)
15.3. Eastern Europe, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
15.4. Eastern Europe, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
15.5. Eastern Europe, Respiratory Diseases Drugs Market Metrics
15.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2025, Eastern Europe Countries
15.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2020, Eastern Europe Countries
15.6. Eastern Europe Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7. Eastern Europe Respiratory Diseases Drugs Market: Country Analysis
15.7.1. Czech Republic Respiratory Diseases Drugs Market,
15.7.1.1. Czech Republic Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.2. Poland Respiratory Diseases Drugs Market
15.7.2.1. Poland Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.3. Romania Respiratory Diseases Drugs Market
15.7.3.1. Romania Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4. Russia Respiratory Diseases Drugs Market
15.7.4.1. Russia Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4.2. Russia Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16. North America Respiratory Diseases Drugs Market
16.1. North America Respiratory Diseases Drugs Market Overview
16.2. North America, Respiratory Diseases Drugs Market, 2020, by Country, Value ($ Billion)
16.3. North America, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
16.4. North America, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
16.5. North America, Respiratory Diseases Drugs Market Metrics
16.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2025, North America Countries
16.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2020, North America Countries
16.6. North America Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7. North America Respiratory Diseases Drugs Market: Country Analysis
16.7.1. Canada Respiratory Diseases Drugs Market
16.7.1.1. Canada Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.2. Mexico Respiratory Diseases Drugs Market
16.7.2.1. Mexico Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3. USA Respiratory Diseases Drugs Market
16.7.3.1. USA Respiratory Diseases Drugs Market Overview
16.7.3.2. USA Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3.3. USA Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17. South America Respiratory Diseases Drugs Market
17.1. South America Respiratory Diseases Drugs Market Overview
17.2. South America, Respiratory Diseases Drugs Market, 2020, by Country, Value ($ Billion)
17.3. South America, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
17.4. South America, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
17.5. South America, Respiratory Diseases Drugs Market Metrics
17.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2025, South America Countries
17.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2020, South America Countries
17.6. South America Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7. South America Respiratory Diseases Drugs Market: Country Analysis
17.7.1. Argentina Respiratory Diseases Drugs Market
17.7.1.1. Argentina Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2. Brazil Respiratory Diseases Drugs Market
17.7.1.1. Brazil Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2.2. Brazil Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.3. Chile Respiratory Diseases Drugs Market
17.7.3.1. Chile Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.4. Colombia Respiratory Diseases Drugs Market
17.7.4.1. Colombia Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.5. Peru Respiratory Diseases Drugs Market
17.7.5.1. Peru Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.6. Venezuela Respiratory Diseases Drugs Market
17.7.6.1. Venezuela Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18. Middle East Respiratory Diseases Drugs Market
18.1. Middle East Respiratory Diseases Drugs Market Overview
18.2. Middle East, Respiratory Diseases Drugs Market, 2020, by Country, Value ($ Billion)
18.3. Middle East, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
18.4. Middle East, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
18.5. Middle East, Respiratory Diseases Drugs Market Metrics
18.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2025, Middle East Countries
18.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2020, Middle East Countries
18.6. Middle East Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7. Middle East Respiratory Diseases Drugs Market: Country Analysis
18.7.1. Saudi Arabia Respiratory Diseases Drugs Market
18.7.1.1. Saudi Arabia Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.2. Israel Respiratory Diseases Drugs Market
18.7.2.1. Israel Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.3. Turkey Respiratory Diseases Drugs Market
18.7.3.1. Turkey Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.4. UAE Respiratory Diseases Drugs Market
18.7.4.1. UAE Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19. Africa Respiratory Diseases Drugs Market
19.1. Africa Respiratory Diseases Drugs Market Overview
19.2. Africa, Respiratory Diseases Drugs Market, 2020, by Country, Value ($ Billion)
19.3. Africa, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
19.4. Africa, Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
19.5. Africa, Respiratory Diseases Drugs Market Metrics
19.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2025, Africa Countries
19.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2020, Africa Countries
19.6. Africa Respiratory Diseases Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7. Africa Respiratory Diseases Drugs Market: Country Analysis
19.7.1. Egypt Respiratory Diseases Drugs Market
19.7.1.1. Egypt Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.2. Nigeria Respiratory Diseases Drugs Market
19.7.2.1. Nigeria Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.3. South Africa Respiratory Diseases Drugs Market
19.7.3.1. South Africa Respiratory Diseases Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
20. Respiratory Diseases Drugs Market Competitive Landscape
20.1. Competitive Market Overview
20.2. Market Shares
20.3. Company Profiles
20.3.1. GlaxosmithKline Plc
20.3.1.1. Company Overview
20.3.1.2. Products and Services
20.3.1.3. Strategy
20.3.1.4. Financial Performance
20.3.2. AstraZeneca Plc
20.3.2.1. Company Overview
20.3.2.2. Products and Services
20.3.2.3. Strategy
20.3.2.4. Financial Performance
20.3.3. Merck & Co
20.3.3.1. Company Overview
20.3.3.2. Products and Services
20.3.3.3. Strategy
20.3.3.4. Financial Performance
20.3.4. Novartis AG
20.3.4.1. Company Overview
20.3.4.2. Products and Services
20.3.4.3. Strategy
20.3.4.4. Financial Performance
20.3.5. Johnson & Johnson
20.3.5.1. Company Overview
20.3.5.2. Products and Services
20.3.5.3. Strategy
20.3.5.4. Financial Performance
21. Key Mergers and Acquisitions in the Respiratory Diseases Drugs Market
22. Market Background: Pharmaceutical Drugs Market
22.1. Pharmaceutical Drugs Market Characteristics
22.2. Pharmaceutical Drugs Market Historic and Forecast, 2015-2020, 2020-2025F, 2030F Growth, by Segment, Value ($ Billion), Global
22.3. Global Pharmaceutical Drugs Market, 2020, by Region, Value ($ Billion)
22.4. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
22.5. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Segmentation by Type, Value ($ Billion)
23. Recommendations
23.1. Global Respiratory Diseases Drugs Market in 2025 - Growth Countries
23.2. Global Respiratory Diseases Drugs Market in 2025 - Growth Segments
23.3. Global Respiratory Diseases Drugs Market in 2025 - Growth Strategies
24. Appendix
24.1. NAICS Definitions of Industry Covered in This Report
24.2. Abbreviations
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher
25. Copyright and Disclaimer

Executive Summary

Major companies in the respiratory diseases drugs market include GlaxosmithKline Plc; AstraZeneca Plc; Merck & Co; Novartis AG and Johnson & Johnson.

The global respiratory diseases drugs market is expected to decline from $90.32 billion in 2020 to $79.82 billion in 2021 at a compound annual growth rate (CAGR) of -11.6%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $98.81 billion in 2025 at a CAGR of 5%.

The respiratory diseases drugs market consists of sales of respiratory diseases drugs and related services by entities (organizations, sole traders and partnerships) that produce drugs to treat respiratory diseases such as asthma, acute bronchitis, emphysema, cystic fibrosis and other diseases. This industry includes establishments that produce anti-asthmatics and COPD drugs to prevent acute attacks caused by respiratory diseases and cough and cold preparations to treat cough and cold. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral®, Coldrex® and Lemsip®. The respiratory diseases drugs market is segmented into anti-asthmatics and copd drugs; and cough and cold preparations.

North America was the largest region in the global respiratory diseases drugs market, accounting for 48% of the market in 2020. Western Europe was the second largest region accounting for 19% of the global respiratory diseases drugs market. Africa was the smallest region in the global respiratory diseases drugs market.

Companies manufacturing respiratory drugs are increasingly using biomarkers in the drug development process to reduce the time taken to bring the product into the market. Biomarkers are biological indicators which are objectively measured and evaluated for biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. It can also help predict the drug efficacy faster than conventional clinical endpoints, the point at which an undesired or abnormal effect of the drug is observed indicating withdrawal from therapy. Companies in this market are investing in the development of biomarkers for use in various activities such as tracking drug activity, the pharmacodynamics (relationship between the drug concentration at the site of action and the biochemical and physiological effect) of drugs and to study diseases and treatment pathways. Companies such as Genentech and Janssen are increasingly investing in the use of biomarkers for understanding the efficacy of a potential respiratory drug. For example, Janssen has partnership with U-BIOPRED (unbiased biomarkers in prediction of respiratory disease outcomes), a group in Europe that aims to understand more about severe asthma.

Companies in the respiratory drugs market are offering drugs for customized individual treatment for better treatment against respiratory diseases. Personalized medicine, also referred to as precision medicine, aims to provide medical care according to the patient’s individual characteristics and genetic makeup. Precision therapies are increasingly being adopted in the respiratory drugs market as firms increasingly let go of the one-size-fits-all model for common respiratory conditions. Companies such as GSK, Teva Pharmaceuticals and AstraZeneca have already invested in personalized medicine for respiratory issues such as asthma. For example, PTC Therapeutics, is developing a drug, which aims to cater to a respiratory mutation which affects about 10% of the population.

During the historic period, the growth of the respiratory diseases drugs market was restrained by patent expiration of branded respiratory diseases drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this negatively impacts the growth of the market in terms of value.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • GlaxosmithKline Plc
  • AstraZeneca Plc
  • Merck & Co
  • Novartis AG
  • Johnson & Johnson

Methodology

Loading
LOADING...